|
1
|
Sospedra M and Martin M: Immunology of
multiple sclerosis. Annals Review Immunology. 23:683–747. 2005.
View Article : Google Scholar
|
|
2
|
Cucci A, Barbero P, Clerico M, Ferrero B,
Versino E, Contessa G, Demercanti S, Viglietta E, Di Liberto A, Vai
AG and Durelli L: Pro-inflammatory cytokine and chemokine mRNA
blood level in multiple sclerosis is related to treatment response
and interferon-beta dose. J Neuroimmunol. 226:150–157. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Graber JJ, Ford D, Zhan M, Francis G,
Panitch H and Dhib-Jalbut S: Cytokine changes during
interferon-beta therapy in multiple sclerosis: correlation with
interferon dose and MRI response. J Neuroimmunol. 185:168–174.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dihb-Jalbut S, Arnold DL, Cleveland DW,
Fisher M, Friedlander RM, Mouradian MM, Przedborski S, Trapp BD,
Wyss-Coray T and Yong VW: Neurodegeneration and neuroprotection in
multiple sclerosis and other neurodegenerative diseases. J
Neuroimmunol. 176:198–215. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang WX, Huang P and Hillert J: Increased
expression of caspase-1 and interleukin-18 in peripheral blood
mononuclear cells in patients with multiple sclerosis. Mult Scler.
10:482–487. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Imitola J, Chitnis T and Khoury SJ:
Cytokines in multiple sclerosis: from bench to bedside. Pharmacol
Ther. 106:163–177. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sutton CE, Lalor SJ, Sweeney CM, Brereton
CF, Lavelle EC and Mills KH: Interleukin-1 and IL-23 induce innate
IL-17 production from gammadelta T cells, amplifying Th17 responses
and autoimmunity. Immunity. 31:331–341. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sweeney CM, Lonergan R, Basdeo SA,
Kinsella K, Dungan LS, Higgins SC, Kelly PJ, Costelloe L, Tubridy
N, Mills KH and Fletcher JM: IL-27 mediates the response to IFN-β
therapy in multiple sclerosis patients by inhibiting Th17 cells.
Brain Behav Immun. 25:1170–1181. 2011.
|
|
9
|
Domingues HS, Mues M, Lassmann H, Wekerle
H and Krishnamoorthy G: Functional and pathogenic differences of
Th1 and Th17 cells in experimental autoimmune encephalomyelitis.
PLoS One. 5:e155312010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rudick RA and Rosahoff RM: Cytokine
secretion by multiple sclerosis monocytes. Arch Neurol. 49:265–270.
1992. View Article : Google Scholar
|
|
11
|
Duddy ME, Armstrong MA, Crockard AD and
Hawkins SA: Changes in plasma cytokines induced by interferon-beta
1a treatment in patients with multiple sclerosis. J Neuroimmunol.
101:98–109. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kurtzke JF: Rating neurologic impairment
in multiple sclerosis: an expanded disability status scale (EDSS).
Neurology. 33:1444–1452. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kermode AG, Thompson AJ, Tofts P, Macmanus
DG, Kendall BE, Kingsley DP, Moseley IF, Rudge P and McDonald WI:
Breakdown of the blood-brain barrier precedes symptoms and other
MRI signs of new lesions in multiple sclerosis. Brain.
113:1477–1489. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Barkhof F: MRI in multiple sclerosis:
correlation with expanded disability status scale (EDSS). Mult
Scler. 5:283–286. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rieckmann P, Albrecht M, Kitze B, Weber T,
Tumani H, Broocks A, Lüer W and Poser S: Cytokine mRNA levels in
mononuclear blood cells from patients with multiple sclerosis.
Neurology. 44:1523–1526. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Olsson T: Cytokine-producing cells in
experimental autoimmune encephalomyelitis and multiple sclerosis.
Neurology. 45(Suppl 6): S11–S15. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Okuda Y, Sakoda S, Fujimura H, Saeki Y,
Kishimoto T and Yanagihara T: IL-6 plays a crucial role in the
induction phase of myelin olygodendrocyte glucoprotein 35–55
induced experimental autoimmune encephalocyelitis. J Neuroimmunol.
10:188–196. 1999.PubMed/NCBI
|
|
18
|
Kraus J, Kuehne BS, Tofighi J,
Frielinghaus P, Stolz E, Blaes F, Laske C, Engelhardt B, Traupe H,
Kaps M and Oschmann P: Serum cytokine levels do not correlate with
disease activity and severity assessed by brain MRI in multiple
sclerosis. Acta Neurol Scand. 105:300–308. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Trenova AG, Manova MG, Kostadinova II,
Hrsitova DR, Vasileva TV and Zahariev ZI: Clinical and laboratory
study of pro-inflammatory and anti-inflammatory cytokines in women
with multiple sclerosis. Folia Med (Plovdiv). 53:29–35.
2011.PubMed/NCBI
|
|
20
|
Obradović D, Kataranovski M, Dincić E,
Obradović S and Colić M: Tumor necrosis factor-alpha and
interleukin-4 in cerbrospinal fluid and plasma in different
clinical forms of multiple sclerosis. Vojnosanit Pregl. 69:151–156.
2012.PubMed/NCBI
|
|
21
|
Polman CH, Reingold SC, Edan G, Filippi M,
Hartung HP, Kappos L, Lublin FD, Metz LM, Mcfarland HF, O'Connor
PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG and Wolinsky
JS: Diagnostic criteria for multiple sclerosis: 2005 revisions to
the ‘McDonald Criteria’. Ann Neurol. 58:840–846. 2005.
|
|
22
|
Polman CH, Reingold SC, Banwell B, Clanet
M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M,
Kappos L, Lublin FD, Montalban X, O'Connor PK, O'Connor PW,
Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinchenker BG and
Wolinsky JS: Diagnostic Criteria for Multiple Sclerosis: 2010
Revision to the McDonald Criteria. Am Neurol. 69:292–302. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lublin FD and Reingold SC: Defining the
clinical course of multiple sclerosis: results of an international
survey. National Multiple Sclerosis Society (USA) Advisory
Committee on Clinical Trials of New Agents in Multiple Sclerosis.
Neurology. 46:907–911. 1996. View Article : Google Scholar
|
|
24
|
Kamali-Sarvestani E, Nikseresht A, Aflaki
E, Sarvari J and Gharesi-Fard B: TNF-α, TNF-β and IL-4 gene
polymorphisms in Iranian patients with multiple sclerosis. Acta
Neurol Scand. 115:161–166. 2007.
|
|
25
|
Wu J-S, James I, Qiu W, Castley A,
Christiansen FT, Carroll WM, Mastaglia FL and Kermode AG: HLA-DRB1
allele heterogeneity influences multiple sclerosis severity as well
as risk in Western Australia. J Neuroimmunol. 219:109–113. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Comini-Frota ER, Rodrigues DH, Miranda EC,
Drum DG, Kaimen-Maciel DR, Donadi EA and Teixeira AL: Serum levels
of brain-derived neurotrophic factor correlate with the number of
T2 MRI lesions in multiple sclerosis. Braz J Med Biol Res.
45:68–71. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ministry of Health National Health
Surveillance Agency Board (ANVISA). Resolution RDC no. 153, June
14, 2004. Official Gazette. 24–Jun. 2004, Brazil: (In
Portuguese).
|
|
28
|
Teunissem CE, Petzold A, Bennetm JL,
Berven FS, Brudin L, Comabella M, Franciotta D, Frederiksen JL,
Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Johson MH, Krasulova
E, Kuhle J, Magnone MC, Rjda C, Schimidt HK, Van Pesch V, Waubant
E, Wolf C, Giovannoni G, Hemmer B, Tumani H and Deisenhammer F: A
consensus protocol of the standardization of cerebral fluid
collection and biobanking. Neurology. 73:1914–1922. 2009.
View Article : Google Scholar
|
|
29
|
Bielekova B and Martin R: Development of
biomarkers in multiple sclerosis. Brain. 127:1463–1478. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Giovannoni G, Green AJ and Thompson EJ:
Are there any body fluid markers of brain atrophy in multiple
sclerosis? Mult Scler. 4:138–142. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Luomala M, Lehtimäki T, Huhtala H, Ukkonen
M, Koivula T, Hurme H and Elovaara I: Promoter polymorphism of
IL-10 and severity of multiple sclerosis. Acta Neurol Scand.
108:396–400. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pulkkinen K, Luomala M, Kuusisto H,
Lehtimäki T, Saarela M, Jalonen TO and Elovaara I: Increased in
CCR5 Delta32/Delta32 genotype in multiple sclerosis. Acta Neurol
Scand. 109:342–347. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bahreini SA, Jabalameli MR, Saadatnia M
and Zahednasab H: The role of non-HLA single nucleotide
polymorphisms in multiple sclerosis susceptibility. J Neuroimmunol.
229:5–15. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Voskuhl RR and Gold SM: Sex-related
factors in multiple sclerosis susceptibility and progression. Nat
Rev Neurol. 8:255–263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ebers GC: PRISMS (Prevention of Relapses
and Disability by Interferon β-1a Subcutaneously in Multiple
Sclerosis) Study Group. Randomized double blind placebo controlled
study interferon beta 1a in relapsing/remitting multiples
sclerosis. Lancet. 352:1498–1504. 1998.
|
|
36
|
Goodin DS, Frohman EM, Garmany GP Jr,
Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH and van
den Noort S: Disease modifying therapies in multiple sclerosis:
reports of the therapeutics and technology assessment subcommittee
of American Academy of Neurology and the MS Council for Clinical
Practice Guidelines. Neurology. 22:169–178. 2002. View Article : Google Scholar
|
|
37
|
Raivich G and Banati R: Brain microglia
and blood-derived macrophages: molecular profiles and functional
roles in multiple sclerosis and animal models of autoimmune
demyelinating disease. Brain Res Rev. 46:161–181. 2004. View Article : Google Scholar
|
|
38
|
Chen YC, Yang X, Miao L, Liu ZG, Li W,
Zhao ZX, Sun XL, Jiang GX, Chen SD and Cheng Q: Serum level of
interleukin-6 in Chinese patients with multiple sclerosis. J
Neuroimmunol. 15:109–111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nguyen LT, Ramanathan M, Weinstock-Guttman
B, Baier M, Brownscheidle C and Jacobs LD: Sex differences in in
vitro pro-inflammatory cytokine production from peripheral blood of
multiple sclerosis patients. J Neurol Sci. 209:93–99. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ramgolam VS, Sha Y, Jin J, Zhang X and
Markovic-Plese S: IFN-beta inhibits human Th17 cell
differentiation. J Immunol. 183:5418–5427. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
John GR, Lee SC, Song X, Rivieccio M and
Brosnan CF: IL-1-regulated responses in astrocytes: relevance to
injury and recovery. Glia. 49:161–176. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Carlson NG, Wieggel WA, Chen J, Bacchi A,
Rogers SW and Gahring LC: Inflammatory cytokines IL-1 alpha, IL-1
beta, IL-6 and TNF-alpha impart neuroprotection to an excitotoxin
through distinct pathways. J Immunol. 163:3963–3968.
1999.PubMed/NCBI
|
|
43
|
Navikas V, Matusevicius D, Söderström M,
Fredrikson S, Kivisäkk P, Ljungdahl A, Höjeberg B and Link H:
Increased interleukin-6 mRNA expression in blood and cerebrospinal
fluid mononuclear cells in multiple sclerosis. J Neuroimmunol.
64:63–69. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Imamura K, Suzumura A, Hayashi F and
Marunouchi T: Cytokine production by peripheral blood
monocytes/macrophages in multiple sclerosis patients. Acta Neurol
Scand. 87:281–285. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Eugster HP, Frei K, Kopf M, Lassmann H and
Fontana A: IL-6-deficient-mice resist myelin oligodendrocyte
glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol.
28:2178–2187. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Schindler R, Mancilla J, Endres S,
Ghorbani R, Clark SC and Dinarello CA: Correlations and
interactions in the production of interleukin-6 (IL-6), IL-1 and
tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6
suppresses IL-1 and TNF. Blood. 75:40–47. 1990.PubMed/NCBI
|
|
47
|
Tilg H, Trehu E, Atkins MB, Dinarello CA
and Mier JW: Interleukin-6 (IL-6) as an anti-inflammatory cytokine:
induction of circulating IL-1 receptor antagonist and soluble tumor
necrosis factor receptor p55. Blood. 83:113–118. 1994.PubMed/NCBI
|
|
48
|
Navikas V, Link J, Palasik W, Söderstrom
M, Fredrikson S, Olsson T and Link H: Increased mRNA expression of
IL-10 in mononuclear cells in multiple sclerosis and optic
neuritis. Scand J Immunol. 41:171–178. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hirano T: Interleukin-6. The Handbook of
Cytokines. Thompson: Academic Press; London: pp. 145–169. 1994
|
|
50
|
Cooke A: Th17 cells in inflammatory
conditions. Rev Diabet Stud. 3:72–75. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Brucklacher-Waldert V, Stuerner K, Kolster
M, Wolthausen J and Tolosa E: Phenotypical and functional
characterization of T helper 17 cells in multiple sclerosis. Brain.
132:3329–3341. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Langrish CL, Chen Y, Blumenschein WM,
Mattson J, Basham B, Sedgwick JD, Mcclanahan T, Kastelein RA and
Cua DJ: IL-23 drives a pathogenesis T cell population that induces
autoimmune inflammation. J Exp Med. 20:233–240. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Harrington LE, Mangan PR and Weaver CT:
Expanding the effector CD4 T-cell repertoire: the Th17 lineage.
Curr Opn Immunol. 18:349–356. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Van Wagoner NJ and Benveniste EN:
Interleukin-6 expression and regulation in astrocytes. J
Neuroimmunol. 100:124–139. 1999.PubMed/NCBI
|
|
55
|
Windhagen A, Newcombe J, Dangond F, Strand
C, Woodroof MN, Cuzner ML and Hafler DA: Expression of
costimulatory molecules B7-1 (CD28), B7-2 (CD86) and interleukin 12
cytokine in multiple sclerosis lesions. J Exp Med. 182:1985–1996.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Campbell IL, Stalder AK, Akwa Y,
Pagenstecher A and Asensio VC: Transgenic models to study the
actions of cytokines in the central nervous system.
Neuroimmunomodulation. 5:126–135. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Byrnes AA, Mcarthur JC and Karp CL:
Interferon-beta therapy for multiple sclerosis induces reciprocal
changes in interleukin-12 and interleukin-10 production. Ann
Neurol. 51:165–174. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wang X, Chen M, Wandinger KP, Willians G
and Dhib-Jalbut S: IFN-beta-1b inhibits IL-12 production in
peripheral blood mononuclear cells in an IL-10-dependent mechanism:
relevance to IFN-beta-1b therapeutic effects in multiple sclerosis.
J Immunol. 165:548–557. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kuchroo VK, Das MP, Brown JA, Ranger AM,
Zamvil SS, Sobel RA, Weiner HL, Nabavi N and Glimcher LH: B7-1 and
B7-2 costimulatory molecules activate differentially the Th1/Th2
developmental pathways: application to autoimmune disease therapy.
Cell. 80:707–718. 1995. View Article : Google Scholar
|
|
60
|
Mikulkova Z, Praksova P, Stourac P,
Bednarik J and Michalek J: Imbalance in T-cell and cytokine
profiles in patients with relapsing-remitting multiple sclerosis. J
Neurol Sci. 300:135–141. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Begolka WS and Miller SD: Cytokines as
intrinsic and exogenous regulators of pathogenesis in experimental
autoimmune encephalomyelitis. Res Immunol. 149:771–781.
1998.PubMed/NCBI
|
|
62
|
Cannella B and Raine CS: The adhesion
molecule and cytokine profile of multiple sclerosis lesions. Annals
Neurol. 37:424–435. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Samoilova EB, Horton JL and Chen Y:
Acceleration of experimental autoimmune encephalomyelitis in
interleukin-10-deficient mice: roles of interleukin-10 in disease
progression and recovery. Cell Immunol. 188:118–124. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Marques M: Multiple sclerosis - Forms and
phases of the disease. Multiple Sclerosis Introduction. Pedrosa R:
(Elaborated by the Neurology Portuguese Society). 1st edition.
Biogen Indec Portugal; Lisboa: pp. 155–161. 2010
|
|
65
|
Brandão CO, Ruocco HH, Farias Ados S,
Oliveira C, Hallal-Longo DE, Mirandola SR, Oliveira EC, Cendes F,
Damasceno BP and Santos LM: Cytokines and intrathecal IgG synthesis
in multiple sclerosis patients during clinical remission. Arq Neuro
Psiquiatr. 63:914–919. 2005.PubMed/NCBI
|
|
66
|
Beck J, Rondot P, Catinot L, Falcoff E,
Kirchner H and Wietzerbin J: Increased production of interferon
gamma and tumor necrosis factor precedes clinical manifestations in
multiple sclerosis: do cytokines trigger off exacerbations? Acta
Neurol Scand. 78:318–323. 1998. View Article : Google Scholar
|
|
67
|
Becher B, Giacomini PS, Pelletier D,
Mccrea E, Prat A and Antel JP: Interferon-gamma secretion by
peripheral blood T-cell subsets in multiple sclerosis: correlation
with disease phase and interferon-beta therapy. Ann Neurol.
45:247–250. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Pouly S, Becher B, Blain M and Antel JP:
Interferon-gamma modulates human oligodendrocyte susceptibility to
Fas-mediated apoptosis. J Neuropathol Exp Neurol. 59:280–286.
2000.PubMed/NCBI
|
|
69
|
Ehling R, Gassner Ch, Lutterotti A,
Strasser-Fuchs S, Kollegger H, Kristoferitsh W, Reindl M and Berger
T: Genetic variants in the tumor necrosis factor receptor II gene
in patients with multiple sclerosis. Tissue Antigens. 63:28–33.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Benvenuto R, Paroli M, Buttinelli C,
Franco A, Barnaba V, Fieschi C and Balsano F: Tumor necrosis
factor-alpha synthesis by cerebrospinal-fluid-derived T cell clones
from patients with multiple sclerosis. Clin Exp Immunol. 84:97–102.
1991.PubMed/NCBI
|
|
71
|
Selmaj K, Raine CS, Cannella B and Brosnan
CF: Identification of lymphotoxin and tumor necrosis factor in
multiple sclerosis lesions. J Clin Invest. 87:949–954. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Schönrock LM, Gawlowski G and Brück W:
Interleukin-6 expression in human multiple sclerosis lesions.
Neurosci Lett. 294:45–48. 2000.
|
|
73
|
van Boxel-Dezaire AH, Hoff SC, Van Oosten
BW, Verweij CL, Dräger AM, Adèr HJ, Van Houwelingen JC, Barkhof F,
Polman CH and Nagelkerkern L: Decreased interleukin-10 and
increased interleukin-12p40 mRNA are associated with disease
activity and characterize different disease stages in multiple
sclerosis. Ann Neurol. 45:695–703. 1999.PubMed/NCBI
|
|
74
|
Iwakura Y and Ishigame H: The IL-23/IL-17
axis in inflammation. J Clin Invest. 116:1218–1222. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Lock C, Hermans G, Pedotti R, Brendolan A,
Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard
J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg
JR, Raine CS, Heller R and Steinman L: Gene-microarray analysis of
multiple sclerosis lesions yields new targets validated in
autoimmune encephalomyelitis. Nat Med. 8:500–508. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Pelfrey CM, Rudick RA, Cotleur AC, Lee JC,
Tary-Lehmann M and Lehmann PV: Quantification of self-recognition
in multiple sclerosis by single cell analysis of cytokine
production. J Immunol. 165:1641–1651. 2000. View Article : Google Scholar : PubMed/NCBI
|
